Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban

JAMA Internal Medicine

Volumn 174, Issue 10, 2014, Pages 1683-1686

  Liakoni, Evangelia ^a   Rätz Bravo, Alexandra E ^a   Terracciano, Luigi ^b   Heim, Markus ^a   Krähenbühl, Stephan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BILIRUBIN; DIPYRONE; GAMMA GLUTAMYLTRANSFERASE; IBUPROFEN LYSINE; LEVOTHYROXINE SODIUM; LISINOPRIL; PANTOPRAZOLE; RIVAROXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CASE REPORT; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER INJURY; LIVER NECROSIS; LOSS OF APPETITE; MALE; MIDDLE AGED; NAUSEA; OSTEOSYNTHESIS; PRURITUS; TIBIA FRACTURE; TOTAL KNEE REPLACEMENT; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; KNEE ARTHROPLASTY; LIVER; LIVER CELL; NECROSIS; PATHOLOGY; PRIMARY PREVENTION; PROCEDURES; TIBIAL FRACTURES; VENOUS THROMBOSIS;

AGED; ARTHROPLASTY, REPLACEMENT, KNEE; FACTOR XA INHIBITORS; FEMALE; FRACTURE FIXATION, INTERNAL; HEPATOCYTES; HUMANS; HYPERBILIRUBINEMIA; LIVER; MALE; MIDDLE AGED; MORPHOLINES; NECROSIS; PRIMARY PREVENTION; THIOPHENES; TIBIAL FRACTURES; VENOUS THROMBOSIS;

EID: 84907964271     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.3912     Document Type: Article

References (15)

1. Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10(1):61-75.
2. Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013;69(9): 1617-1633.
3. Gong IY, Kim RB. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29(7)(suppl):S24-S33.
4. Bondarenko M, Curti C, Montana M, Rathelot P, Vanelle P. Efficacy and toxicity of factor Xa inhibitors. J Pharm Pharm Sci. 2013;16(1):74-88.
5. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010;103(3):572-585.
6. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34(3):243-252.
7. Russmann S, Niedrig DF, Budmiger M, et al. Rivaroxaban postmarketing risk of liver injury. J Hepatol. 2014;61(2):293-300.
8. Björnsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther. 2006;79(6):521-528.
9. Bénichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol. 1990;11(2):272-276.
10. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-1259.
11. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-739.
12. Suzuki A, Andrade RJ, Bjornsson E, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010;33(6):503-522.
13. Gulmez SE, Larrey D, Pageaux GP, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013;36(2): 135-144.
14. Cordes A, VogtW, Maier KP. Pantoprazoleinduced hepatitis [in German]. Dtsch Med Wochenschr. 2003;128(12):611-614.
15. Ratanasavanh D, Beaune P, Morel F, Flinois JP, Guengerich FP, Guillouzo A. Intralobular distribution and quantitation of cytochrome P-450 enzymes in human liver as a function of age. Hepatology. 1991;13(6):1142-1151.